10x Genomics Stock News

Understanding the State of the Genomics Market

The Genomics provides an overview of the complete set of genetic commands provided by the DNA, while transcriptomics looks into gene appearance patterns. The studies of all genes and their associated mRNAs are correspondingly called genomics and transcriptomics. Genomics reveals

DekaBank Deutsche Girozentrale raised its holdings in 10x Genomics, Inc. (NASDAQ:TXG) by 560.2% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 45,379 shares of the companys stock after acquiring an additional 38,505 shares during the quarter. DekaBank Deutsche Girozentrales holdings in 10x Genomics were []

10x Genomics Inc. (NASDAQ:TXG) price on Friday, December 10, fall -2.83% below its previous days close as a downside momentum from buyers pushed the stocks value to $139.51. A look at the stocks price movement, the close in the last trading session was $143.57. Turning to its 52-week performance, $208.99 and $128.15 were the 52-week 10x Genomics Inc. (TXG) Price Target And Rating Are Reviewed By Analysts. Read More »

10x Genomics, Inc. (NASDAQ:TXG) CEO Serge Saxonov sold 15,000 shares of the stock in a transaction on Tuesday, December 7th. The stock was sold at an average price of $145.97, for a total transaction of $2,189,550.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this […]

ARLINGTON, Va., Dec. 8, 2021 /PRNewswire/ -- BioInformatics Inc., part of Science and Medicine Group, the leading research and advisory firm serving the life science tools market, today announced that nine companies have been selected for a Life Science Industry Award for launching one of

Slow Capital Inc. grew its position in 10x Genomics, Inc. (NASDAQ:TXG) by 6.5% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 9,176 shares of the companys stock after purchasing an additional 562 shares during the quarter. Slow Capital Inc.s holdings in 10x Genomics were worth $1,336,000 as of its most recent SEC []

Comerica Bank raised its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 34.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,364 shares of the company’s stock after acquiring an additional 606 shares during the quarter. Comerica Bank’s holdings in 10x Genomics […]

10x Genomics, Inc. (NASDAQ:TXG) Director John R. Stuelpnagel sold 5,000 shares of the stock in a transaction dated Wednesday, December 1st. The shares were sold at an average price of $151.16, for a total value of $755,800.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this []

Related Stocks: TXG ,

10x Genomics, Inc. (NASDAQ:TXG) insider Benjamin J. Hindson sold 41,666 shares of 10x Genomics stock in a transaction on Wednesday, December 1st. The shares were sold at an average price of $148.08, for a total value of $6,169,901.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be []

DUBLIN, Dec. 2, 2021 /PRNewswire/ -- The "Whole Genome and Exome Sequencing Markets by Application, Organism and Product with Executive and Consultant Guides. Includes Direct to Consumer Analysis - 2022 to 2026 " report has been added to ResearchAndMarkets.com''s offering. The COVID

10x Genomics, Inc. (NASDAQ:TXG) Director Sridhar Kosaraju sold 1,500 shares of the companys stock in a transaction that occurred on Wednesday, November 24th. The shares were sold at an average price of $150.06, for a total transaction of $225,090.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is []

Analysts forecast that 10x Genomics, Inc. (NASDAQ:TXG) will report sales of $147.92 million for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for 10x Genomics earnings. The lowest sales estimate is $145.70 million and the highest is $150.00 million. 10x Genomics reported sales of $112.22 million in the same quarter last []

10x Genomics, Inc. (NASDAQ:TXG) insider Benjamin J. Hindson sold 351 shares of the firms stock in a transaction that occurred on Monday, November 22nd. The stock was sold at an average price of $148.38, for a total value of $52,081.38. The transaction was disclosed in a filing with the SEC, which is accessible through the []